MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 4 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $25,000 | -59.7% | 20,558 | +3.0% | 0.00% | – |
| Q1 2017 | $62,000 | -28.7% | 19,968 | -6.1% | 0.00% | – |
| Q4 2016 | $87,000 | -35.6% | 21,259 | 0.0% | 0.00% | – |
| Q3 2016 | $135,000 | +17.4% | 21,259 | 0.0% | 0.00% | – |
| Q2 2016 | $115,000 | -32.0% | 21,259 | +5.0% | 0.00% | – |
| Q1 2016 | $169,000 | +11.9% | 20,249 | +5.8% | 0.00% | – |
| Q4 2015 | $151,000 | -5.0% | 19,135 | +2.7% | 0.00% | – |
| Q3 2015 | $159,000 | -34.0% | 18,634 | -4.5% | 0.00% | – |
| Q2 2015 | $241,000 | +9.5% | 19,522 | +5.1% | 0.00% | – |
| Q1 2015 | $220,000 | +14.0% | 18,578 | +8.6% | 0.00% | – |
| Q4 2014 | $193,000 | +27.0% | 17,113 | -1.2% | 0.00% | – |
| Q3 2014 | $152,000 | +16.0% | 17,322 | -3.7% | 0.00% | – |
| Q2 2014 | $131,000 | -23.8% | 17,984 | -60.2% | 0.00% | – |
| Q3 2013 | $172,000 | – | 45,232 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 5,000,000 | $20,400,000 | 4.19% |
| Consonance Capital Management LP | 9,067,998 | $36,997,000 | 4.06% |
| Lagoda Investment Management, L.P. | 1,522,529 | $6,212,000 | 2.13% |
| INDUS CAPITAL PARTNERS, LLC | 1,050,000 | $4,284,000 | 0.56% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 9,072,877 | $37,017,000 | 0.32% |
| GARRISON BRADFORD & ASSOCIATES INC | 77,700 | $317,000 | 0.29% |
| Cannell & Co. | 1,572,978 | $6,418,000 | 0.23% |
| Virtus ETF Advisers LLC | 179,625 | $733,000 | 0.22% |
| LeJeune Puetz Investment Counsel LLC | 3,976 | $161,000 | 0.12% |
| STONERIDGE INVESTMENT PARTNERS LLC | 221,838 | $905,000 | 0.12% |